Analystreport

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Guggenheim from $103.00 to $120.00. They now have a "buy" rating on the stock

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com